Genmab — December 2018
-
-
-
Bluebird/Celgene bb21217 BCMA CAR-T https://www.marketwatch.com/press-release/bluebird-bio-and-celgene-corporation-present-initial-data-from-ongoing-phase-1-clinical-study-of-next-generation-anti-bcma-car-t-cell-therapy-bb21217-in-patients-with-relapsedrefractory-multiple-myeloma-at-ash-annual-meeting-2018-12-02
-
God morgen.
-
Genopfriskning på R&D Update i dag. https://ir.genmab.com/news-releases/news-release-details/genmab-hold-rd-update-and-2018-ash-data-review-meeting-0
-
https://www.youtube.com/watch?v=iemqPGiyapY Promising Findings for Daratumumab Plus VRd in Multiple Myeloma
-
-
argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110) https://globenewswire.com/news-release/2018/12/03/1660451/0/en/argenx-enters-exclusive-global-collaboration-and-license-agreement-with-Cilag-GmbH-International-an-affiliate-of-Janssen-for-cusatuzumab-ARGX-110.html#.XATcYy5wP0U.twitter
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind